Jacqueline Shea compensation by year
INOVIO PHARMACEUTICALS Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $335,000 | $430,769 | $467,585 | $729,758 | $750,615 | $728,000 | $728,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $181,000 | $1,499,996 | $750,726 | $1,171,474 | $491,873 | $490,819 | $346,101 |
| Option awards | $465,120 | $0 | $860,581 | $1,268,362 | $812,999 | $475,977 | $351,955 |
| Non-equity incentive | $165,760 | $193,600 | $218,442 | $336,000 | $371,280 | $340,704 | $144,144 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $10,154 | $12,946 | $12,823 | $13,524 | $12,141 | $15,169 | $16,955 |
| Total | $1,157,034 | $2,137,311 | $2,310,157 | $3,519,118 | $2,438,908 | $2,050,669 | $1,587,155 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INOVIO PHARMACEUTICALS, INC. DEF 14A filed April 7, 2026, accession 0001055726-26-000011, and prior-year filings. Open the filing on EDGAR.
How this page was built: the INOVIO PHARMACEUTICALS, INC. filed document, accession 0001055726-26-000011. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 85,201 | $148,250 | — |
| RSU | 84,888 | $147,705 | — |
| RSU | 37,263 | $64,838 | — |
| PSU | 18,592 | $32,350 | — |
| RSU | 17,744 | $30,875 | — |
| PSU | 9,960 | $17,330 | — |
| Option | 105,262 | — | $2.13 |
| Option | 17,433 | — | $14.88 |
| Option | 34,866 | — | $8.46 |
| Option | 52,824 | — | $1.94 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INOVIO PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
8 Form 4 lines since the FY2025 proxy (filed April 7, 2026)current to 2026-11-05 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-20 | Exercise or conversion | — | 28,296 | — | 123,327 |
| 2026-05-20 | Tax withholding | — | 12,306 | $1.23 | 111,021 |
| 2026-05-20 | Grant or award derivative | — | 123,760 | $0.00 | 123,760 |
| 2026-05-20 | Exercise or conversion derivative | — | 28,296 | $0.00 | 56,592 |
| 2026-05-20 | Grant or award derivative | — | 100,240 | $0.00 | 100,240 |
| 2026-05-15 | Exercise or conversion | — | 17,744 | — | 102,748 |
| 2026-05-15 | Exercise or conversion derivative | — | 17,744 | $0.00 | 0 |
| 2026-05-15 | Tax withholding | — | 7,717 | $1.30 | 95,031 |
The 8 most recent of 8 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
INOVIO PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jacqueline Shea · this page | President, Chief Executive Officer and Director | $1,587,155 |
| Michael Sumner | Chief Medical Officer and Head of Development | $910,636 |
| Peter Kies | Chief Financial Officer | $833,684 |
Board service
INOVIO PHARMACEUTICALS board · FY2025How this board is paid
Company policy: INOVIO PHARMACEUTICALS pays directors a $45,000 cash retainer. As stated in INOVIO PHARMACEUTICALS's FY2025 proxy.
The full INOVIO PHARMACEUTICALS compensation record
free company briefThis page is one person within INOVIO PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the INOVIO PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order INOVIO PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INOVIO PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order INO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.